New antibody-generating tool aims to fight COVID-19, other diseases miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: HHMI announces the selection of 21 exceptional early career scientists as 2020 Hanna Gray Fellows to support diversity in biomedical research. The 2022 Hanna H. Gray Fellows Program competition will. view more
Credit: HHMI
Twenty-one outstanding scientists. Eight years of financial support. One tight-knit community.
Today, the Howard Hughes Medical Institute (HHMI) announced the selection of the 2020 Hanna Gray Fellows, a cohort of 21 early career researchers who are taking on some of the biggest challenges in the life sciences, such as understanding the innerworkings of the brain or the complexities of the immune system. By unlocking basic principles, their work could one day ease symptoms in patients with chronic pain, treat kids suffering from pediatric leukemia, and spark new therapeutics for emerging infectious diseases.
Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies
Financing will support development of novel IL-2 treatments for various diseases
CHARLOTTESVILLE, Va., Jan. 19, 2021 /PRNewswire/ Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology s GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., management and others. Slate is a pre-clinical biotechnology company developing paradigm shifting IL-2 compounds based on research conducted at the University of Virginia School of Medicine. IL233, Slate s lead candidate, is a first in class drug that induces persistent remission in animal models of autoimmune and inflammatory diseases.